AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00251004
Drug: Corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral corticosteroids were administered according to local practice during the trial. At the same center, all patients were to follow the same steroid administration protocol.
Trial: NCT04056897
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: intravenous infusion in combination with placebo tablet daily. The total duration of blinded therapy is 100 weeks
Trial: NCT02674191
Drug: (150g Clindamycin/tds) for 1 week
RxNorm normalized name: Clindamycin for Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative antibiotic
Trial: NCT02674191
Drug: (Cataflam 25mg), are prescribed post-operatively
FDA approved: no
EMA approved: no
PMDA approved: no
Description: an analgesic
Trial: NCT00557583
Drug: VBY 376
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doses of 50mg and higher or placebo will be evaluated.
Trial: NCT04241185
Drug: Fluorouracil (5-FU)
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU administered via IV infusion at a dose of 500 mg per cubic meter of body volume on Days 1-5 and 22-26.
Trial: NCT03181763
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive inactive placebo on their second visit.
Trial: NCT01847807
Drug: low dose Astragalus
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02456662
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo (identical to study medication- ondansetron) PO 30 minutes prior to 200mg PO doxycycline
Trial: NCT01244490
Drug: Placebo Comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02763969
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00002975
Drug: aminolevulinic acid
RxNorm normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01453387
Drug: MSC2015103B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 1: MSC2015103B will be administered orally once weekly on Days 1, 8, and 15 of a 21-day cycle until MTD establishment. Starting dose will be 150 microgram (mcg), which will be escalated to 200 mcg, 300 mcg, 450 mcg, 650 mcg, 1000 mcg and 1500 mcg subsequently.
Trial: NCT01453387
Drug: MSC2015103B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Schedule 2: MSC2015103B will be administered orally thrice weekly on Days 1, 3, 5, 8, 10, 12, 15, 17 and 19 of a 21-day cycle until MTD was established. Starting dose will be 150 mcg, and will be escalated to 200 mcg subsequently.
Trial: NCT01466543
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02960893
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Randomization Phase: Matching placebo loose filled capsule.
Trial: NCT00954252
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo, oral capsule, single dose
Trial: NCT01173887
Drug: VCAP/AMP/VECP(mLSG15)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCAP(Vincristine Sulfate, Cyclophosphamide Hydrate, Doxorubicin Hydrochloride, Prednisolone); AMP(Doxorubicin Hydrochloride, Ranimustine, Prednisolone); VECP(Vindesine Sulfate, Etoposide, Carboplatin, Prednisolone)
Trial: NCT03156127
Drug: BR-UPS 5 mg tablet, Inisia 5 mg tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects of Control group will be first orally administered with inisia 5mg tablet . After washout period of 2 weeks, They will be orally administered with BR-UPS 5mg tablet. On the contrary, Subjects of Test group will be first orally administered with BR-UPS 5mg tablet. After washout period of 2 weeks, They will be orally administered with inisia 5mg tablet.
Trial: NCT03268902
Drug: Azithromycin Oral Liquid Product
RxNorm normalized name: azithromycin Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azithromycin 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months
Trial: NCT01479556
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150mg BID p.o.
Trial: NCT02176720
Drug: FDOPA PET
RxNorm normalized name: Pet Pectillin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[18F\]FDOPA radiopharmaceutical will be intravenousely injected for PET-CT scanning of the brain.
Trial: NCT03078530
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a pill with inactive ingredients
Trial: NCT03078530
Drug: Visbiome
RxNorm normalized name: Visbiome
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a probiotic mixture available to randomized study participants, starting with subject 29
Trial: NCT03078530
Drug: VSL#3
RxNorm normalized name: VSL#3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This is a probiotic mixture available to the first 28 subjects randomized to the study
Trial: NCT00634192
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 1x300mg/d inhaled
Trial: NCT00634192
Drug: tobramycin
RxNorm normalized name: Tobramycin
DrugBank: Tobramycin (DB00684)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 2x300mg/d inhaled
Trial: NCT03268902
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contain inert excipients only. Azithromycin placebo 20 mg/kg administered by study personnel at 6, 9, 12 and 15 months. Nitazoxanide placebo 100 mg given twice daily for 3 days at 12 and 15 months.~Mothers in the nicotinamide placebo arm will be given placebo 250 mg daily from delivery through 6 months post-partum in capsule form.~Children in the nicotinamide placebo arm will be given 100 mg/d of placebo in powder form between 6 and 18 months of age
Trial: NCT02842086
Drug: F/TAF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT02842086
Drug: F/TDF Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tablet administered orally once daily
Trial: NCT00283400
Drug: 25% human albumin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 25% human albumin: after approval by the Data and Safety Monitoring Board dosage tier would be escalated to the subsequent higher level sequentially.
Trial: NCT00768105
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosing to match AZD1656
Trial: NCT03208218
Drug: SYP-1512
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lenalidomide 25mg/tablet, PO, 1 tablet once daily for I\&II D1(crossover)
Trial: NCT02298595
Drug: BYL719
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200, 250, 300, or 350 mg/day by mouth every day
Trial: NCT03610646
Drug: MYL-1701P
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive intravitreal injections of MYL-1701P throughout the 52-week treatment period, with the last dose at 48 weeks.~The additional doses may be administered in accordance with the protocol.
Trial: NCT00282347
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo was provided as a sterile solution for injection.
Trial: NCT01855321
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo capsule is to be identical to the cholecalciferol capsule with respect to size and shape and 2) the intervention group will take 1 oral capsule of cholecalciferol 50,000 IU (Bio-Tech Pharmacal, Fayetteville, AR USA) once weekly for 8 weeks followed by 50,000 IU once monthly for 4 months.
Trial: NCT00282347
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02980029
Drug: TVB-2640
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TVB-2640 is a potent and reversible inhibitor of the FASN enzyme. TVB-2640 inhibits the β-ketoacyl reductase (KR) enzymatic activity of the FASN enzyme. TVB-2640 is uncompetitive towards both NADPH and acetoacetyl-CoA in inhibiting KR activity.
Trial: NCT03596086
Drug: ADV/HSV-tk (gene therapy)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational adenovirus gene therapy injected at tumor site followed by valacyclovir, radiotherapy, and chemotherapy
Trial: NCT02490527
Drug: Simvastatin (40mg)
RxNorm normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: A cholesterol-lowering medication that blocks the production of cholesterol.
Trial: NCT04242368
Drug: Isotonic saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal isotonic saline irrigation (240 mL, 0.9% NaCl) administered through nasal rinse bottle.
Trial: NCT04242368
Drug: Hypertonic Nasal Wash
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal hypertonic saline irrigation (240 mL, 1.8% NaCl) administered through nasal rinse bottle.
Trial: NCT03275454
Drug: BIVV009 6.5 grams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.
Trial: NCT03275454
Drug: BIVV009 7.5 grams
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
Trial: NCT00871507
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo suspension/solution and Placebo capsule administered as single doses
Trial: NCT03451227
Drug: Remifentanil Group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Remifentanil HCL will be infused at 0.01-0.2 mcg/kg/min titrated to sedation level (SAS less than or equal to 4) and cardiovascular parameters (within 30% of baseline). The infusion will be stopped at the end of the procedure.
Trial: NCT02147262
Drug: doxycycline orally, 100 mg, bid, 14 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00004904
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02147262
Drug: doxycycline orally, 100 mg, bid, 28 days
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03371680
Drug: Injection of 1-13 Carbon Leucine and deuterated water
RxNorm normalized name: Sodium salt of carbonic acid
DrugBank: Sodium carbonate (DB09460)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All patients received a constant intravenous infusion of 1 g 1-13 Carbon Leucine (Cambridge Isotope Laboratories, Andover, MA) dissolved in saline for 24 h. Deuterated water (Cambridge Isotope Laboratories, Andover, MA) was administered as a 25 ml bolus at the study start and then, every 12 hours over the next 36 hours, as intermittent boluses corresponding to 0.0625% of fluid intake, to maintain steady state of deuterium enrichment in body water
Trial: NCT04946474
Drug: Xingnaojing injection + Shuxuetong oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xingnaojing injection (administered immediately after joining the group, once a day, treatment for 10 days) + Naoxueshu oral liquid treatment (administered on the 4th day of onset, 3 times a day, treatment for 30 days ).
Trial: NCT01300533
Drug: BIND-014
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02183103
Drug: meloxicam rapid release tablet, 12mg, UH AC62MU
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00003273
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00003273
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT03612713
Drug: Placebo First
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be given placebo one hour before fMRI scan. After at least 1 week wash out participants will be given 15mg oxycodone one hour before fMRI scan.
Trial: NCT00925938
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT02858297
Drug: Glucosamine sulfate
RxNorm normalized name: Glucosamine Sulfate
DrugBank: Glucosamine (DB01296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Glucosamine (GlcN) is an N-deacetyl amino sugar derived from the complete hydrolysis of chitosan with recently reported immunoregulatory capacity and anti-inflammatory effect
Trial: NCT01099709
Drug: Reformulated OXY (oxycodone HCl)
RxNorm normalized name: Oxy Gard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reformulated OXY 10-mg tablet x 1 dose taken with food.
Trial: NCT01099709
Drug: Original OxyContin® (OXY) (oxycodone HCl)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Original OxyContin® (OXY) 10-mg tablet x 1 dose taken with food.
Trial: NCT01031225
Drug: STA 9090
FDA approved: no
EMA approved: no
PMDA approved: no
Description: STA-9090 IV infusion once per week for three consecutive weeks followed by a 1 week dose-free interval
Trial: NCT00117884
Drug: 851B
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 851B 0.15% formulation, gel, topically, twice a week for 2 cycles.
Trial: NCT01103401
Drug: Drug: Tobramycin 0.3% - Dexamethasone 0.1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: one drop four times per day
Trial: NCT01103401
Drug: Drug: Tobramycin-Dexamethasone plus Ketorolac tromethamine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tobramycin-Dexamethasone one drop four times per day and Ketorolac tromethamine one drop three times per day
Trial: NCT03768557
Drug: Minocycline
RxNorm normalized name: Minocycline
DrugBank: Minocycline (DB01017)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Minocycline (200mg)
Trial: NCT00695604
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo via MDI.
Trial: NCT00376714
Drug: GSK233705
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02531971
Drug: Intravenous fentanyl citrate
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 100 micrograms (2 millilitres) via intravenous injection
Trial: NCT02531971
Drug: Duragesic®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Trial: NCT02531971
Drug: Mylan generic fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: TDDS dosage is 25 micrograms/hour (worn for 72 h)
Trial: NCT01389362
Drug: Placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 sachets to be taken daily
Trial: NCT00552617
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: After induction of anesthesia an intubation dose of NMBA was administered IV: either 0.9 mg/kg rocuronium (arm 1) or 0.1 mg/kg vecuronium (arm 6).~Maintenance doses of 0.1-0.2 mg/kg rocuronium IV or 0.02-0.03 mg/kg vecuronium IV could be administered if necessary.~At reappearance of T2 the randomized single dose of Placebo IV was administered
Trial: NCT02125617
Drug: Prednisolone
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10 mg/day
Trial: NCT00943553
Drug: Induction Chemotherapy
RxNorm normalized name: human sputum, Bordetella pertussis infected
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm B - 7 days (7 days of induction chemotherapy with IV daunorubicin 45 mg/m\^2 and cytarabine 100 mg/m\^2/day only)
Trial: NCT01803035
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00154336
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02149212
Drug: Phlebotonic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aminaftone -- 75 mg BID
Trial: NCT00393952
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is a HFA pMDI that delivers placebo aerosol. Patients will take 2 actuations BID for 12 weeks.
Trial: NCT00403754
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo to indacaterol was provided in powder filled capsules with a single dose dry powder inhaler (SDDPI).
Trial: NCT00338377
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/d by vein over 2 hours on Days -7 and -6 before T cell infusion
Trial: NCT02225054
Drug: Normal Saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL 0.9%
Trial: NCT02093650
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy bean oil
Trial: NCT01528540
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: This group will include placebo.
Trial: NCT00817778
Drug: AZD1656
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Trial: NCT00817778
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be treated with tolerable dose twice daily for another 24 days.
Trial: NCT04715737
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administration of placebo intranasally
Trial: NCT01133990
Drug: FOLFIRI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FOLFIRI will be administered as IV infusion on Days 1 and 15 of each cycle, and 5-FU at 400 mg/m\^2 as an IV bolus injection followed by a total of 2400 mg/m2 by CIV infusion over 46 hours over Days 1 and 2 via an ambulatory programmable pump. The 5-FU IV bolus (400 mg/m\^2) and CIV infusion (2400 mg/m\^2) over 46 hours is repeated on Days 15 and 16 of each cycle.
Trial: NCT00649155
Drug: Cipro® XR Tablets (500 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500mg, single dose fasting
Trial: NCT00005866
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: arm 2: 60 mg/kg every 24 hrs for 2 doses, IV over 2 hrs, days -5 and -4
Trial: NCT00005866
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: GVHD: 15 mg/m2 day 1, 10 mg/m2 day 3, 6 and 11 by IV
Trial: NCT04575597
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching molnupiravir administered orally in capsule form every 12 hours for 5 days (10 doses total)
Trial: NCT01653132
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile, preservative free 0.9% saline, 1 ml, was used as placebo, and injected into the parotid (0.2 ml each) and submandibular (0.3ml each) glands .
Trial: NCT00976118
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: matching placebo to masitinib
Trial: NCT00041587
Drug: IL13-PE38QQR
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04607928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comparing the effect of pirfenidone in avoiding establishing or progression of fibrosis induced after COVID19 infection
Trial: NCT03255070
Drug: ARX788
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An antibody drug conjugate
Trial: NCT00539201
Drug: GSK706769
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03131466
Drug: Nerve block
RxNorm normalized name: Nerve Block Tray 22g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The radiofrequency generator will be set at the sensory stimulating mode, and the lowest frequency of 0.2 V will be used for 360s-sham PRF treatment, after which 1.4 mL of a mixture of 2 mg of dexamethasone sodium phosphate and 1 mL of 1% plain lidocaine will be slowly injected through the radiofrequency treatment cannula needle. Before the needle being removed, 0.5 mL of normal saline will be injected.
Trial: NCT02866370
Drug: Pegylated Liposomal Doxorubicin (PLD)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ovarian Cancer Patients Pegylated Liposomal Doxorubicin (PLD) (40mg/m2) IV every 28 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.
Trial: NCT02866370
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Endometrial Cancer Patients Doxorubicin IV 60mg/m2 every 21 days\*~\* Patients will usually receive up to 6 cycles of chemotherapy. If in the opinion of the Investigator, a patient would benefit from continuing with chemotherapy beyond 6 cycles, it is acceptable to continue until progression or unacceptable toxicity. The maximal lifetime cumulative dose of doxorubicin or pegylated liposomal doxorubicin allowed is 450 mg/m2.
Trial: NCT02093468
Drug: MST-188
RxNorm normalized name: MST 600
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03671590
Drug: TG-1701
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral daily dose
Trial: NCT04678206
Drug: BLU-5937
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of BLU-5937 Tablets
Trial: NCT04678206
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral administration of matching placebo for BLU-5937 Tablets
Trial: NCT00126880
Drug: AVX754
FDA approved: no
EMA approved: no
PMDA approved: no
Description: apricitabine, 600mg BID or 800mg BID
Trial: NCT02726308
Drug: 10 ml/kg Ringer's lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative 10 ml/kg Ringer's lactate solution .
Trial: NCT02726308
Drug: 30 ml/kg Ringer's lactate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-operative 30 ml/kg Ringer's lactate solution .
Trial: NCT03207438
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo